

Ohio Provider Communications

Anthem expands specialty pharmacy medical step therapy drug list*

Published: Feb 1, 2019

The following clinical criteria will be effective May 1, 2019.

Colony Stimulating Factor Agents ING-CC-0002

Effective for dates of service on and after May 1, 2019, the following specialty pharmacy codes from new or current criteria will be included in our existing specialty pharmacy medical step therapy review process. Zarxio® will be the preferred short-acting colony stimulating factor (CSF) agent over Neupogen®, Granix®, and Nivestym™.

Anthem's prior authorization clinical review of these specialty pharmacy drugs will be managed by AIM Specialty Health® (AIM), a separate company.

Additional information regarding biosimilar drugs can be found by viewing the reference document, [Biosimilar Drugs - What are they?](#) here.

To access the clinical criteria information please visit our [Clinical Criteria](#) website.

| Clinical Criteria | Status | Drug | HCPCS or CPT Code | NDC Code |
|--------------------------|---------------------|-------------|--------------------------|--|
| ING-CC-0002 | Preferred Agent | Zarxio® | Q5101 | 61314-0304-01 61314-0304-10 61314-0312-01 61314-0312-10 61314-0318-01 61314-0318-10 61314-0326-01 61314-0326-10 |
| ING-CC-0002 | Non-Preferred Agent | Neupogen® | J1442 | 55513-0530-01 55513-0530-10 55513-0546-01 55513-0546-10 55513-0924-01 55513-0924-10 55513-0924-91 55513-0209-01 55513-0209-10 55513-0209-91 |

Ohio Provider Communications

| | | | | |
|-------------|---------------------|-----------------------|-------|--|
| ING-CC-0002 | Non-Preferred Agent | Granix [®] | J1447 | 63459-0910-11 63459-0910-12 63459-0910-15 63459-0910-17 63459-0910-36 63459-0912-11 63459-0912-12 63459-0912-15 63459-0912-17 63459-0912-36 |
| ING-CC-0002 | Non-Preferred Agent | Nivestym [™] | Q5110 | 00069-0291-10 00069-0291-01 00069-0292-01 00069-0292-10 |

<https://providernews.anthem.com/ohio/article/anthem-expands-specialty-pharmacy-medical-step-therapy-drug-list-3>

Featured In:

February 2019 Anthem Ohio Provider Newsletter

1 Related Attachment:

- Anthem_FAQ_Biosimilars_Feb 2019.pdf